• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Montagu and Kohlberg to Acquire Teleflex Medical OEM in a Carve-out Transaction

    12/9/25 9:20:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email

    Leading Medical Device Designer & Manufacturer to Operate as Independent Company Following Closing of Transaction

    Montagu and Kohlberg, two leading middle-market private equity firms, today announced that they have entered into a definitive agreement to acquire Teleflex Medical OEM (the "Company") from Teleflex Incorporated (NYSE:TFX) for $1.5 billion in a carve-out transaction.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208550931/en/

    For over 40 years, Teleflex Medical OEM has developed and supplied custom-engineered interventional catheter components and sub-assemblies, as well as surgical fibers and sutures, used across fast-growing treatment areas – including structural heart, neurovascular, electrophysiology and urology – that rely on advanced materials and precision manufacturing to improve surgical outcomes and patients' lives. With seven state-of-the-art facilities across the U.S., Mexico, and Ireland, the Company leverages its complex extrusion expertise, breadth of offering, and vertically integrated operating model to support a blue-chip customer base of medical device companies worldwide.

    Following the closing of the transaction, which is expected in the second half of 2026 subject to customary regulatory approvals and other closing conditions, the Company will operate as an independent, global contract developer and manufacturer ideally positioned to bring innovative solutions to market at pace, with the strategic focus and operational flexibility to scale its model. Greg Stotts, who joined Teleflex in 2006 and currently serves as the Company's President and General Manager, will become Chief Executive Officer of the Company at that time, bringing over three decades of industry sales, marketing, sales operations, and manufacturing experience to his new role.

    Mr. Stotts said: "This is a momentous milestone for our team and our customers, and we are excited to work with the Montagu and Kohlberg team to shape the future of Teleflex Medical OEM. As a focused, independent company backed by experienced healthcare investors, we will accelerate investment in innovation, quality systems and capacity while continuing to deliver the reliability and engineering depth our customers expect."

    Montagu and Kohlberg bring leading track records with decades of experience investing in healthcare products and services. The firms' complementary carve-out and value creation expertise will help to ensure Teleflex Medical OEM seamlessly transitions to an independent company while accelerating its growth by expanding its customer base, investing in innovation, people, processes and capabilities.

    Adrien Sassi, Partner at Montagu, added: "We have followed Teleflex Medical OEM for several years, giving us real insight into the caliber of the organization and the opportunity that lies ahead as an independent company. Over the last decade, Teleflex Medical OEM has built a reputation as a leading strategic supplier in the global medtech value chain, known for its engineering support, reliability, and quality. Working with Kohlberg, we look forward to leveraging our carve-out expertise, built through decades of transaction experience, and our strong track record in driving growth acceleration in medical device platforms, to support Greg and his team in unlocking the full potential of the company."

    Matt Jennings, Operating Partner at Kohlberg, will assume the role of Chairman of the Company upon closing of the transaction. Mr. Jennings commented: "Medical device companies are increasingly under pressure to optimize their portfolios and consolidate supply chains to create value for their patients and shareholders. Teleflex Medical OEM has proven itself as a differentiated, integrated, and compliant business uniquely positioned to create long-term mutually beneficial contract development and manufacturing partnerships with customers. We look forward to supporting Greg and the entire Teleflex Medical OEM team to create a bright future for all Company stakeholders as the business scales."

    "Teleflex Medical OEM is an exceptional platform trusted by its customers for its quality, service and delivery," added Chris Anderson, Senior Partner of Kohlberg. "The Company is ideally suited to benefit from Kohlberg's expertise supporting market-leading healthcare platforms, drawing on our deep network of operating executives and our ecosystem of investments and industry relationships. We look forward to working with our partners at Montagu, and together we are confident that Teleflex Medical OEM will thrive as a standalone platform focused on delivering maximum value to its customers."

    Raymond James acted as exclusive financial advisor, and Kirkland & Ellis and Ropes & Gray served as legal counsels to Montagu and Kohlberg.

    About Teleflex Medical OEM

    Teleflex Medical OEM is a leading contract developer and manufacturer of custom-engineered interventional catheter components and sub-assemblies, as well as surgical fibers and sutures. With seven sites across the U.S., Mexico, and Ireland, the Company combines deep materials expertise with vertically integrated manufacturing and dedicated EPIC design centers to help customers bring high-performance medical devices to market.

    About Montagu

    Montagu is a leading mid-market private equity firm, committed to finding and growing businesses that make the world work. Focusing on businesses with a must-have product or service in a structurally growing marketplace, Montagu brings proven growth capabilities to help companies achieve their ambitions and unlock their full potential. Montagu specializes in carve-out and other first-time buyout investments and has deep expertise in five priority sectors: Healthcare, Financial Sector Services, Critical Data, Digital Infrastructure and Education. ESG forms an integral part of its strategy, and its commitment to responsible investment is fully integrated into its investment and value-creation process. Montagu has €14 billion of assets under management.

    For more information, please visit www.montagu.com.

    About Kohlberg

    Founded in 1987, Kohlberg is a leading U.S. middle market private equity firm based in Mount Kisco, New York. The firm invests in leading healthcare and services companies characterized by strong market positions, recurring revenue streams and resilient end markets, which it identifies through rigorous thematic research grounded in its White Paper Program. Leveraging its team of investment and operating professionals, Kohlberg works with management teams to accelerate growth, enhance operational excellence and create value. As of September 30, 2025, Kohlberg manages approximately $17 billion on behalf of investors globally.

    For more information, please visit www.kohlberg.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251208550931/en/

    Media enquiries – Montagu

    Greenbrook: James Madsen, Cecilie Oerting

    +44 20 7952 2000 | [email protected]



    Media enquiries – Kohlberg

    Gasthalter & Co.: Amanda Shpiner, Jonathan Warren

    +1 212-257-4170 | [email protected]

    Get the next $TFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/27/2026$128.00Mkt Perform → Outperform
    Raymond James
    1/27/2026$138.00Hold → Buy
    Needham
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President & CFO Deren John was granted 13,784 shares and covered exercise/tax liability with 229 shares, increasing direct ownership by 300% to 18,073 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    3/5/26 5:59:07 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    CVP, General Counsel & Secty Logue Daniel V. was granted 9,853 shares and covered exercise/tax liability with 131 shares, increasing direct ownership by 65% to 24,653 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    3/5/26 5:59:14 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Corp. VP & Chief HR Officer Hicks Cameron P was granted 8,096 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 70% to 19,363 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    3/5/26 5:59:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teleflex upgraded by Raymond James with a new price target

    Raymond James upgraded Teleflex from Mkt Perform to Outperform and set a new price target of $128.00

    3/27/26 8:44:32 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex upgraded by Needham with a new price target

    Needham upgraded Teleflex from Hold to Buy and set a new price target of $138.00

    1/27/26 8:35:45 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex downgraded by BofA Securities with a new price target

    BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

    3/4/25 7:44:32 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    SEC Filings

    View All

    Teleflex Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TELEFLEX INC (0000096943) (Filer)

    3/27/26 2:48:47 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Teleflex Incorporated

    SCHEDULE 13G/A - TELEFLEX INC (0000096943) (Subject)

    3/27/26 1:35:24 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated filed SEC Form 8-K: Other Events

    8-K - TELEFLEX INC (0000096943) (Filer)

    3/17/26 4:45:39 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Irenic Comments on Teleflex's Announcement That It Is Open to Strategic Alternatives

    Calls on Board to Establish Strategic Review Sub-Committee with New Independent Directors to Oversee Process Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today issued the following statement regarding the Company's recent announcement: "We welcome Teleflex's newfound openness to consider all strategic alternatives. As a next step, we believe the Board of Directors should form a Strategic Review sub-committee with new independent directors, including a shareholder representative and excluding Dr. Klasko, to work with its advisors to both engage with inbound approaches and solicit outb

    3/27/26 2:31:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution

    Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.

    3/27/26 12:57:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors

    Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company's Sustained Value Destruction, Lack of Permanent Leadership, and Board's Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today sent the below letter to the Company's Board of Directors (the "Board") regarding its refusal to engage with potential acquirors, despite receiv

    3/27/26 7:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    View All

    Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution

    Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.

    3/27/26 12:57:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Teleflex Announces Leadership Transition

    Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that Stuart Randle, a member of the Company's Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who departs as Chairman, President and CEO of the Company. Dr. Stephen Klasko, the Company's Lead Director, has been named Chairman of the Board. The Board has engaged Spencer Stuart, a leading execu

    1/8/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Financials

    Live finance-specific insights

    View All

    Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors

    Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company's Sustained Value Destruction, Lack of Permanent Leadership, and Board's Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today sent the below letter to the Company's Board of Directors (the "Board") regarding its refusal to engage with potential acquirors, despite receiv

    3/27/26 7:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Quarterly Dividend

    Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 31, 2026, to shareholders of record at the close of business on March 6, 2026. Additional information about Teleflex can be obtained from the company's website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency me

    2/26/26 6:45:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports 2025 Financial Results and Full Year 2026 Outlook

    Announces Restructuring to Right-Size and Reduce Cost Structure Related to Announced Strategic Divestitures Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the year ended December 31, 2025. Full year 2025 continuing operations financial summary1 GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period1 Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis2 GAAP diluted EPS from continuing operations of $1.31, compared to $1.21 in the prior year period Adjusted diluted EPS from contin

    2/26/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/14/24 1:28:29 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/8/24 10:29:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    2/14/24 10:04:36 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care